Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Pharmacologic Treatment of Restless Legs Syndrome

Author(s): Qing Lv, Xinlin Wang, Tetsuya Asakawa* and Xiao Ping Wang*

Volume 19, Issue 3, 2021

Published on: 30 December, 2020

Page: [372 - 382] Pages: 11

DOI: 10.2174/1570159X19666201230150127

open access plus

Abstract

Restless legs syndrome (RLS)/Willis-Ekbom disease is a neurologic disorder characterized by a strong desire to move when at rest (usually in the evening) and paraesthesia in their lower legs. The most widely used therapies for first-line treatment of RLS are dopaminergic drugs; however, their long-term use can lead to augmentation. α2δ Ligands, opioids, iron, glutamatergic drugs, adenosine, and sleep aids have been investigated as alternatives. The pathogenesis of RLS is not well understood. Despite the efficacy of dopaminergic drugs in the treatment of this disorder, unlike in Parkinson’s disease dopaminergic cell loss in the substantia nigra has not been observed in RLS. The etiology of RLS is likely complex, involving multiple neural pathways. RLS-related genes identified in genome-wide association studies can provide insight into the mechanistic basis and pathophysiology of RLS. Here we review the current treatments and knowledge of the mechanisms underlying RLS.

Keywords: Restless legs syndrome, dopaminergic drugs, nondopaminergic drugs, mechanisms, genetic factors, augmentation.

« Previous Next »
Graphical Abstract

[1]
Allen, R.P.; Picchietti, D.; Hening, W.A.; Trenkwalder, C.; Walters, A.S.; Montplaisi, J. Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med., 2003, 4(2), 101-119.
[http://dx.doi.org/10.1016/S1389-9457(03)00010-8] [PMID: 14592341]
[2]
Earley, C.J.; Heckler, D.; Allen, R.P. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med., 2005, 6(4), 301-305.
[http://dx.doi.org/10.1016/j.sleep.2005.01.008] [PMID: 15978514]
[3]
Earley, C.J.; Silber, M.H. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med., 2010, 11(9), 807-815.
[http://dx.doi.org/10.1016/j.sleep.2010.07.007] [PMID: 20817595]
[4]
Winkelman, J.W.; Redline, S.; Baldwin, C.M.; Resnick, H.E.; Newman, A.B.; Gottlieb, D.J. Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study. Sleep, 2009, 32(6), 772-778.
[http://dx.doi.org/10.1093/sleep/32.6.772] [PMID: 19544754]
[5]
Akpinar, S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch. Neurol., 1982, 39(11), 739.
[http://dx.doi.org/10.1001/archneur.1982.00510230065027] [PMID: 7126008]
[6]
Micozkadioglu, H.; Ozdemir, F.N.; Kut, A.; Sezer, S.; Saatci, U.; Haberal, M. Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: an open-label study. Ren. Fail., 2004, 26(4), 393-397.
[http://dx.doi.org/10.1081/JDI-120039823] [PMID: 15462107]
[7]
Trenkwalder, C.; Benes, H.; Grote, L.; Happe, S.; Högl, B.; Mathis, J.; Saletu-Zyhlarz, G.M.; Kohnen, R.; Group, C.S. CALDIR Study Group Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov. Disord., 2007, 22(5), 696-703.
[http://dx.doi.org/10.1002/mds.21401] [PMID: 17274039]
[8]
Winkelmann, J.; Allen, R.P.; Högl, B.; Inoue, Y.; Oertel, W.; Salminen, A.V.; Winkelman, J.W.; Trenkwalder, C.; Sampaio, C. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov. Disord., 2018, 33(7), 1077-1091.
[http://dx.doi.org/10.1002/mds.27260] [PMID: 29756335]
[9]
Winkelman, J.W.; Armstrong, M.J.; Allen, R.P.; Chaudhuri, K.R.; Ondo, W.; Trenkwalder, C.; Zee, P.C.; Gronseth, G.S.; Gloss, D.; Zesiewicz, T. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 2016, 87(24), 2585-2593.
[http://dx.doi.org/10.1212/WNL.0000000000003388] [PMID: 27856776]
[10]
Trenkwalder, C.; Winkelmann, J.; Inoue, Y.; Paulus, W. Restless legs syndrome-current therapies and management of augmentation. Nat. Rev. Neurol., 2015, 11(8), 434-445.
[http://dx.doi.org/10.1038/nrneurol.2015.122] [PMID: 26215616]
[11]
Wanner, V.; Garcia, M.C.; Romero, S.; Cano-Pumarega, I.; García-Borreguero, D. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome. Adv. Pharmacol., 2019, 84, 187-205.
[http://dx.doi.org/10.1016/bs.apha.2019.02.003] [PMID: 31229171]
[12]
Silber, M.H.; Becker, P.M.; Buchfuhrer, M.J.; Earley, C.J.; Ondo, W.G.; Walters, A.S.; Winkelman, J.W. Scientific and medical advisory board, restless legs syndrome foundation. the appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clin. Proc., 2018, 93(1), 59-67.
[http://dx.doi.org/10.1016/j.mayocp.2017.11.007] [PMID: 29304922]
[13]
Allen, R.P.; Chen, C.; Garcia-Borreguero, D.; Polo, O.; DuBrava, S.; Miceli, J.; Knapp, L.; Winkelman, J.W. Comparison of pregabalin with pramipexole for restless legs syndrome. N. Engl. J. Med., 2014, 370(7), 621-631.
[http://dx.doi.org/10.1056/NEJMoa1303646] [PMID: 24521108]
[14]
Allen, R.; Chen, C.; Soaita, A.; Wohlberg, C.; Knapp, L.; Peterson, B.T.; García-Borreguero, D.; Miceli, J. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med., 2010, 11(6), 512-519.
[http://dx.doi.org/10.1016/j.sleep.2010.03.003] [PMID: 20466589]
[15]
Garcia-Borreguero, D.; Larrosa, O.; Williams, A.M.; Albares, J.; Pascual, M.; Palacios, J.C.; Fernandez, C. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology, 2010, 74(23), 1897-1904.
[http://dx.doi.org/10.1212/WNL.0b013e3181e1ce73] [PMID: 20427750]
[16]
Trenkwalder, C.; Beneš, H.; Grote, L.; García-Borreguero, D.; Högl, B.; Hopp, M.; Bosse, B.; Oksche, A.; Reimer, K.; Winkelmann, J.; Allen, R.P.; Kohnen, R.; Group, R.S. Reloxyn Study Group Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol., 2013, 12(12), 1141-1150.
[http://dx.doi.org/10.1016/S1474-4422(13)70239-4] [PMID: 24140442]
[17]
Winkelmann, J.; Schormair, B.; Lichtner, P.; Ripke, S.; Xiong, L.; Jalilzadeh, S.; Fulda, S.; Pütz, B.; Eckstein, G.; Hauk, S.; Trenkwalder, C.; Zimprich, A.; Stiasny-Kolster, K.; Oertel, W.; Bachmann, C.G.; Paulus, W.; Peglau, I.; Eisensehr, I.; Montplaisir, J.; Turecki, G.; Rouleau, G.; Gieger, C.; Illig, T.; Wichmann, H.E.; Holsboer, F.; Müller-Myhsok, B.; Meitinger, T. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat. Genet., 2007, 39(8), 1000-1006.
[http://dx.doi.org/10.1038/ng2099] [PMID: 17637780]
[18]
Daubian-Nosé, P.; Frank, M.K.; Esteves, A.M. Sleep disorders: A review of the interface between restless legs syndrome and iron metabolism. Sleep Sci., 2014, 7(4), 234-237.
[http://dx.doi.org/10.1016/j.slsci.2014.10.002] [PMID: 26483934]
[19]
Earley, C.J.; Kuwabara, H.; Wong, D.F.; Gamaldo, C.; Salas, R.; Brasic, J.; Ravert, H.T.; Dannals, R.F.; Allen, R.P. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep (Basel), 2011, 34(3), 341-347.
[http://dx.doi.org/10.1093/sleep/34.3.341] [PMID: 21358851]
[20]
Zhao, H.; Zhu, W.; Pan, T.; Xie, W.; Zhang, A.; Ondo, W.G.; Le, W. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J. Neurosci. Res., 2007, 85(5), 1065-1076.
[http://dx.doi.org/10.1002/jnr.21207] [PMID: 17342757]
[21]
Oboshi, Y.; Ouchi, Y.; Yagi, S.; Kono, S.; Nakai, N.; Yoshikawa, E.; Futatsubashi, M.; Terada, T.; Kim, K.; Harada, K. In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study. J. Cereb. Blood Flow Metab., 2012, 32(4), 654-662.
[http://dx.doi.org/10.1038/jcbfm.2011.201] [PMID: 22234337]
[22]
Connor, J.R.; Boyer, P.J.; Menzies, S.L.; Dellinger, B.; Allen, R.P.; Ondo, W.G.; Earley, C.J. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 2003, 61(3), 304-309.
[http://dx.doi.org/10.1212/01.WNL.0000078887.16593.12] [PMID: 12913188]
[23]
Earley, C.J.; Allen, R.P.; Connor, J.R.; Ferrucci, L.; Troncoso, J. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med., 2009, 10(10), 1155-1157.
[http://dx.doi.org/10.1016/j.sleep.2009.01.006] [PMID: 19307154]
[24]
Mochizuki, H.; Choong, C.J.; Baba, K. Parkinson’s disease and iron. J. Neural Transm. (Vienna), 2020, 127(2), 181-187.
[http://dx.doi.org/10.1007/s00702-020-02149-3] [PMID: 32025811]
[25]
Moon, H.J.; Chang, Y.; Lee, Y.S.; Song, H.J.; Chang, H.W.; Ku, J.; Cho, Y.W. T2 relaxometry using 3.0-tesla magnetic resonance imaging of the brain in early- and late-onset restless legs syndrome. J. Clin. Neurol., 2014, 10(3), 197-202.
[http://dx.doi.org/10.3988/jcn.2014.10.3.197] [PMID: 25045371]
[26]
Moon, H.J.; Chang, Y.; Lee, Y.S.; Song, H.; Chang, H.W.; Ku, J.; Allen, R.P.; Earley, C.J.; Cho, Y.W. A comparison of MRI tissue relaxometry and ROI methods used to determine regional brain iron concentrations in restless legs syndrome. Med. Devices (Auckl.), 2015, 8, 341-350.
[PMID: 26257527]
[27]
Rizzo, G.; Manners, D.; Testa, C.; Tonon, C.; Vetrugno, R.; Marconi, S.; Plazzi, G.; Pizza, F.; Provini, F.; Malucelli, E.; Gramegna, L.L.; Lodi, R. Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. Mov. Disord., 2013, 28(13), 1886-1890.
[http://dx.doi.org/10.1002/mds.25576] [PMID: 23780623]
[28]
Patton, S.M.; Ponnuru, P.; Snyder, A.M.; Podskalny, G.D.; Connor, J.R. Hypoxia-inducible factor pathway activation in restless legs syndrome patients. Eur. J. Neurol., 2011, 18(11), 1329-1335.
[http://dx.doi.org/10.1111/j.1468-1331.2011.03397.x] [PMID: 21985026]
[29]
Allen, R.P.; Earley, C.J. Restless legs syndrome: a review of clinical and pathophysiologic features. J. Clin. Neurophysiol., 2001, 18(2), 128-147.
[http://dx.doi.org/10.1097/00004691-200103000-00004] [PMID: 11435804]
[30]
Schormair, B.; Zhao, C.; Bell, S.; Tilch, E.; Salminen, A.V.; Pütz, B.; Dauvilliers, Y.; Stefani, A.; Högl, B.; Poewe, W.; Kemlink, D.; Sonka, K.; Bachmann, C.G.; Paulus, W.; Trenkwalder, C.; Oertel, W.H.; Hornyak, M.; Teder-Laving, M.; Metspalu, A.; Hadjigeorgiou, G.M.; Polo, O.; Fietze, I.; Ross, O.A.; Wszolek, Z.; Butterworth, A.S.; Soranzo, N.; Ouwehand, W.H.; Roberts, D.J.; Danesh, J.; Allen, R.P.; Earley, C.J.; Ondo, W.G.; Xiong, L.; Montplaisir, J.; Gan-Or, Z.; Perola, M.; Vodicka, P.; Dina, C.; Franke, A.; Tittmann, L.; Stewart, A.F.R.; Shah, S.H.; Gieger, C.; Peters, A.; Rouleau, G.A.; Berger, K.; Oexle, K.; Di Angelantonio, E.; Hinds, D.A.; Müller-Myhsok, B.; Winkelmann, J. 23andMe Research Team; DESIR study group. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol., 2017, 16(11), 898-907.
[http://dx.doi.org/10.1016/S1474-4422(17)30327-7] [PMID: 29029846]
[31]
Salminen, A.V.; Lam, D.D.; Winkelmann, J. Role of MEIS1 in restless legs syndrome: From GWAS to functional studies in mice. Adv. Pharmacol., 2019, 84, 175-184.
[http://dx.doi.org/10.1016/bs.apha.2019.03.003] [PMID: 31229170]
[32]
Lyu, S.; Xing, H.; DeAndrade, M.P.; Perez, P.D.; Zhang, K.; Liu, Y.; Yokoi, F.; Febo, M.; Li, Y. The role of BTBD9 in the cerebral cortex and the pathogenesis of restless legs syndrome. Exp. Neurol., 2020, 323113111
[http://dx.doi.org/10.1016/j.expneurol.2019.113111] [PMID: 31715135]
[33]
Lyu, S.; Doroodchi, A.; Xing, H.; Sheng, Y.; DeAndrade, M.P.; Yang, Y.; Johnson, T.L.; Clemens, S.; Yokoi, F.; Miller, M.A.; Xiao, R.; Li, Y. BTBD9 and dopaminergic dysfunction in the pathogenesis of restless legs syndrome. Brain Struct. Funct., 2020, 225(6), 1743-1760.
[http://dx.doi.org/10.1007/s00429-020-02090-x] [PMID: 32468214]
[34]
Ferré, S.; Earley, C.; Gulyani, S.; Garcia-Borreguero, D. In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. Sleep Med., 2017, 31, 86-92.
[http://dx.doi.org/10.1016/j.sleep.2016.08.019] [PMID: 27899234]
[35]
Collado-Seidel, V.; Kazenwadel, J.; Wetter, T.C.; Kohnen, R.; Winkelmann, J.; Selzer, R.; Oertel, W.H.; Trenkwalder, C. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology, 1999, 52(2), 285-290.
[http://dx.doi.org/10.1212/WNL.52.2.285] [PMID: 9932945]
[36]
Guilleminault, C.; Cetel, M.; Philip, P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology, 1993, 43(2), 445.
[http://dx.doi.org/10.1212/WNL.43.2.445] [PMID: 8094897]
[37]
Giorgi, L.; Asgharian, A.; Hunter, B. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clin. Ther., 2013, 35(9), 1321-1336.
[http://dx.doi.org/10.1016/j.clinthera.2013.06.016] [PMID: 23938061]
[38]
Hening, W.A.; Allen, R.P.; Ondo, W.G.; Walters, A.S.; Winkelman, J.W.; Becker, P.; Bogan, R.; Fry, J.M.; Kudrow, D.B.; Lesh, K.W.; Fichtner, A.; Schollmayer, E.; Group, S.P.S. SP792 Study Group. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov. Disord., 2010, 25(11), 1675-1683.
[http://dx.doi.org/10.1002/mds.23157] [PMID: 20629075]
[39]
Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet, 2015, 386(9996), 896-912.
[http://dx.doi.org/10.1016/S0140-6736(14)61393-3] [PMID: 25904081]
[40]
Koblinger, K.; Füzesi, T.; Ejdrygiewicz, J.; Krajacic, A.; Bains, J.S.; Whelan, P.J. Characterization of A11 neurons projecting to the spinal cord of mice. PLoS One, 2014, 9(10)e109636
[http://dx.doi.org/10.1371/journal.pone.0109636] [PMID: 25343491]
[41]
Ondo, W.G.; He, Y.; Rajasekaran, S.; Le, W.D. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov. Disord., 2000, 15(1), 154-158.
[http://dx.doi.org/10.1002/1531-8257(200001)15:1<154:AID-MDS1025>3.0.CO;2-Q] [PMID: 10634257]
[42]
Yepes, G.; Guitart, X.; Rea, W.; Newman, A.H.; Allen, R.P.; Earley, C.J.; Quiroz, C.; Ferré, S. Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann. Neurol., 2017, 82(6), 951-960.
[http://dx.doi.org/10.1002/ana.25104] [PMID: 29171915]
[43]
Stiasny-Kolster, K.; Magerl, W.; Oertel, W.H.; Möller, J.C.; Treede, R.D. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. Brain, 2004, 127(Pt 4), 773-782.
[http://dx.doi.org/10.1093/brain/awh079] [PMID: 14985260]
[44]
Bogan, R.K.; Bornemann, M.A.; Kushida, C.A.; Trân, P.V.; Barrett, R.W.; Group, X.P.S. XP060 Study Group. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin. Proc., 2010, 85(6), 512-521.
[http://dx.doi.org/10.4065/mcp.2009.0700] [PMID: 20511481]
[45]
Lee, D.O.; Ziman, R.B.; Perkins, A.T.; Poceta, J.S.; Walters, A.S.; Barrett, R.W.; Group, X.P.S. XP053 Study Group. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J. Clin. Sleep Med., 2011, 7(3), 282-292.
[http://dx.doi.org/10.5664/JCSM.1074] [PMID: 21677899]
[46]
Inoue, Y.; Hirata, K.; Uchimura, N.; Kuroda, K.; Hattori, N.; Takeuchi, M. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr. Med. Res. Opin., 2013, 29(1), 13-21.
[http://dx.doi.org/10.1185/03007995.2012.746217] [PMID: 23121149]
[47]
Walters, A.S.; Ondo, W.G.; Kushida, C.A.; Becker, P.M.; Ellenbogen, A.L.; Canafax, D.M.; Barrett, R.W.; Group, X.P.S. XP045 Study Group. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin. Neuropharmacol., 2009, 32(6), 311-320.
[http://dx.doi.org/10.1097/WNF.0b013e3181b3ab16] [PMID: 19667976]
[48]
Happe, S.; Sauter, C.; Klösch, G.; Saletu, B.; Zeitlhofer, J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology, 2003, 48(2), 82-86.
[http://dx.doi.org/10.1159/000072882] [PMID: 14504416]
[49]
Thorp, M.L.; Morris, C.D.; Bagby, S.P. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am. J. Kidney Dis., 2001, 38(1), 104-108.
[http://dx.doi.org/10.1053/ajkd.2001.25202] [PMID: 11431189]
[50]
Garcia-Borreguero, D.; Larrosa, O.; de la Llave, Y.; Verger, K.; Masramon, X.; Hernandez, G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology, 2002, 59(10), 1573-1579.
[http://dx.doi.org/10.1212/WNL.59.10.1573] [PMID: 12451200]
[51]
Taylor, C.P.; Angelotti, T.; Fauman, E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res., 2007, 73(2), 137-150.
[http://dx.doi.org/10.1016/j.eplepsyres.2006.09.008] [PMID: 17126531]
[52]
Hendrich, J.; Van Minh, A.T.; Heblich, F.; Nieto-Rostro, M.; Watschinger, K.; Striessnig, J.; Wratten, J.; Davies, A.; Dolphin, A.C. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc. Natl. Acad. Sci. USA, 2008, 105(9), 3628-3633.
[http://dx.doi.org/10.1073/pnas.0708930105] [PMID: 18299583]
[53]
Ondo, W.G. Methadone for refractory restless legs syndrome. Mov. Disord., 2005, 20(3), 345-348.
[http://dx.doi.org/10.1002/mds.20359] [PMID: 15580610]
[54]
Walters, A.S.; Wagner, M.L.; Hening, W.A.; Grasing, K.; Mills, R.; Chokroverty, S.; Kavey, N. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep, 1993, 16(4), 327-332.
[http://dx.doi.org/10.1093/sleep/16.4.327] [PMID: 8341893]
[55]
Walters, A.S.; Winkelmann, J.; Trenkwalder, C.; Fry, J.M.; Kataria, V.; Wagner, M.; Sharma, R.; Hening, W.; Li, L. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov. Disord., 2001, 16(6), 1105-1109.
[http://dx.doi.org/10.1002/mds.1214] [PMID: 11748742]
[56]
Walters, A.S.; Ondo, W.G.; Zhu, W.; Le, W. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study. J. Neurol. Sci., 2009, 279(1-2), 62-65.
[http://dx.doi.org/10.1016/j.jns.2008.12.022] [PMID: 19167016]
[57]
Hagelberg, N.; Kajander, J.K.; Någren, K.; Hinkka, S.; Hietala, J.; Scheinin, H. Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. Synapse, 2002, 45(1), 25-30.
[http://dx.doi.org/10.1002/syn.10078] [PMID: 12112410]
[58]
Trenkwalder, C.; Winkelmann, J.; Oertel, W.; Virgin, G.; Roubert, B.; Mezzacasa, A. FCM-RLS Study Investigators Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Mov. Disord., 2017, 32(10), 1478-1482.
[http://dx.doi.org/10.1002/mds.27040] [PMID: 28643901]
[59]
Cho, Y.W.; Allen, R.P.; Earley, C.J. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Med., 2016, 25, 16-23.
[http://dx.doi.org/10.1016/j.sleep.2016.06.021] [PMID: 27823710]
[60]
Mizuno, S.; Mihara, T.; Miyaoka, T.; Inagaki, T.; Horiguchi, J. CSF iron, ferritin and transferrin levels in restless legs syndrome. J. Sleep Res., 2005, 14(1), 43-47.
[http://dx.doi.org/10.1111/j.1365-2869.2004.00403.x] [PMID: 15743333]
[61]
Allen, R.P.; Picchietti, D.L.; Auerbach, M.; Cho, Y.W.; Connor, J.R.; Earley, C.J.; Garcia-Borreguero, D.; Kotagal, S.; Manconi, M.; Ondo, W.; Ulfberg, J.; Winkelman, J.W. International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med., 2018, 41, 27-44.
[http://dx.doi.org/10.1016/j.sleep.2017.11.1126] [PMID: 29425576]
[62]
Nelson, C.; Erikson, K.; Piñero, D.J.; Beard, J.L. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J. Nutr., 1997, 127(12), 2282-2288.
[http://dx.doi.org/10.1093/jn/127.12.2282] [PMID: 9405575]
[63]
Garcia-Borreguero, D.; Cano, I.; Granizo, J.J. Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel. Sleep Med., 2017, 34, 105-108.
[http://dx.doi.org/10.1016/j.sleep.2017.03.012] [PMID: 28522077]
[64]
Garcia-Borreguero, D.; Guitart, X.; Garcia Malo, C.; Cano-Pumarega, I.; Granizo, J.J.; Ferré, S. Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Med., 2018, 45, 94-97.
[http://dx.doi.org/10.1016/j.sleep.2018.02.002] [PMID: 29680437]
[65]
Sagheb, M.M.; Dormanesh, B.; Fallahzadeh, M.K.; Akbari, H.; Sohrabi Nazari, S.; Heydari, S.T.; Behzadi, S. Efficacy of vitamins C, E, and their combination for treatment of restless legs syndrome in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Sleep Med., 2012, 13(5), 542-545.
[http://dx.doi.org/10.1016/j.sleep.2011.11.010] [PMID: 22317944]
[66]
Tutuncu, M.; Tutuncu, M. The effect of vitamin D on restless legs syndrome: prospective self-controlled case study. Sleep Breath., 2020, 24(3), 1101-1106.
[http://dx.doi.org/10.1007/s11325-019-01984-3] [PMID: 32078093]
[67]
Roshi; Tandon, V.R.; Mahajan, A.; Sharma, S.; Khajuria, V. Comparative efficacy and safety of clonazepam versus nortriptyline in restless leg syndrome among forty plus women: a prospective, open-label randomized study. J Midlife Health, 2019, 10(4), 197-203.
[http://dx.doi.org/10.4103/jmh.JMH_26_18] [PMID: 31942156]
[68]
Saletu, M.; Anderer, P.; Saletu-Zyhlarz, G.; Prause, W.; Semler, B.; Zoghlami, A.; Gruber, G.; Hauer, C.; Saletu, B. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur. Neuropsychopharmacol., 2001, 11(2), 153-161.
[http://dx.doi.org/10.1016/S0924-977X(01)00080-3] [PMID: 11313161]
[69]
Brand, S.; Beck, J.; Hatzinger, M.; Holsboer-Trachsler, E. Patients suffering from restless legs syndrome have low internal locus of control and poor psychological functioning compared to healthy controls. Neuropsychobiology, 2013, 68(1), 51-58.
[http://dx.doi.org/10.1159/000350957] [PMID: 23774053]
[70]
Kurlan, R.; Rabin, M. Augmentation in restless legs syndrome Poor response to sudden withdrawal of dopaminergic therapy. J Parkinsonism Restless Legs Synd, 2013, 3, 49-52.
[http://dx.doi.org/10.2147/JPRLS.S47648]
[71]
Aurora, R.N.; Kristo, D.A.; Bista, S.R.; Rowley, J.A.; Zak, R.S.; Casey, K.R.; Lamm, C.I.; Tracy, S.L.; Rosenberg, R.S. American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep (Basel), 2012, 35(8), 1039-1062.
[http://dx.doi.org/10.5665/sleep.1986] [PMID: 22851801]
[72]
Carlos, K.; Prado, G.F.; Teixeira, C.D.; Conti, C.; de Oliveira, M.M.; Prado, L.B.; Carvalho, L.B. Benzodiazepines for restless legs syndrome. Cochrane Database Syst. Rev., 2017, 3CD006939
[PMID: 28319266]
[73]
Tilch, E.; Schormair, B.; Zhao, C.; Salminen, A.V.; Antic Nikolic, A.; Holzknecht, E.; Högl, B.; Poewe, W.; Bachmann, C.G.; Paulus, W.; Trenkwalder, C.; Oertel, W.H.; Hornyak, M.; Fietze, I.; Berger, K.; Lichtner, P.; Gieger, C.; Peters, A.; Müller-Myhsok, B.; Hoischen, A.; Winkelmann, J.; Oexle, K. Identification of Restless Legs Syndrome Genes by Mutational Load Analysis. Ann. Neurol., 2020, 87(2), 184-193.
[http://dx.doi.org/10.1002/ana.25658] [PMID: 31788832]
[74]
Salminen, A.V.; Garrett, L.; Schormair, B.; Rozman, J.; Giesert, F.; Niedermeier, K.M.; Becker, L.; Rathkolb, B.; Rácz, I.; Klingenspor, M.; Klopstock, T.; Wolf, E.; Zimmer, A.; Gailus-Durner, V.; Torres, M.; Fuchs, H.; Hrabě de Angelis, M.; Wurst, W.; Hölter, S.M.; Winkelmann, J. German Mouse Clinic Consortium Meis1: effects on motor phenotypes and the sensorimotor system in mice. Dis. Model. Mech., 2017, 10(8), 981-991.
[http://dx.doi.org/10.1242/dmm.030080] [PMID: 28645892]
[75]
Meneely, S.; Dinkins, M.L.; Kassai, M.; Lyu, S.; Liu, Y.; Lin, C.T.; Brewer, K.; Li, Y.; Clemens, S. Differential Dopamine D1 and D3 receptor modulation and expression in the spinal cord of two mouse models of restless legs syndrome. Front. Behav. Neurosci., 2018, 12, 199.
[http://dx.doi.org/10.3389/fnbeh.2018.00199] [PMID: 30233336]
[76]
Drgonova, J.; Walther, D.; Wang, K.J.; Hartstein, G.L.; Lochte, B.; Troncoso, J.; Uetani, N.; Iwakura, Y.; Uhl, G.R. Mouse model for protein tyrosine phosphatase D (PTPRD) associations with restless leg syndrome or Willis-Ekbom disease and addiction: reduced expression alters locomotion, sleep behaviors and cocaine-conditioned place preference. Mol. Med., 2015, 21(1), 717-725.
[http://dx.doi.org/10.2119/molmed.2015.00017] [PMID: 26181631]
[77]
Allen, R.P.; Donelson, N.C.; Jones, B.C.; Li, Y.; Manconi, M.; Rye, D.B.; Sanyal, S.; Winkelmann, J. Animal models of RLS phenotypes. Sleep Med., 2017, 31, 23-28.
[http://dx.doi.org/10.1016/j.sleep.2016.08.002] [PMID: 27839945]
[78]
Lyu, S.; Xing, H.; DeAndrade, M.P.; Liu, Y.; Perez, P.D.; Yokoi, F.; Febo, M.; Walters, A.S.; Li, Y. The Role of BTBD9 in striatum and restless legs syndrome. eNeuro, 2019, 6(5), ENEURO.0277- 19.2019..
[http://dx.doi.org/10.1523/ENEURO.0277-19.2019] [PMID: 31444227]
[79]
Allen, R.P.; Earley, C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep, 1996, 19(3), 205-213.
[http://dx.doi.org/10.1093/sleep/19.3.205] [PMID: 8723377]
[80]
Leu-Semenescu, S.; Petiau, C.; Charley Monaca, C.; Dauvilliers, Y. French consensus: Augmentation syndrome in restless legs syndrome. Rev. Neurol. (Paris), 2018, 174(7-8), 532-539.
[http://dx.doi.org/10.1016/j.neurol.2018.06.004] [PMID: 30055794]
[81]
Trenkwalder, C.; Allen, R.; Högl, B.; Clemens, S.; Patton, S.; Schormair, B.; Winkelmann, J. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol., 2018, 17(11), 994-1005.
[http://dx.doi.org/10.1016/S1474-4422(18)30311-9] [PMID: 30244828]
[82]
Garcia-Borreguero, D.; Silber, M.H.; Winkelman, J.W.; Högl, B.; Bainbridge, J.; Buchfuhrer, M.; Hadjigeorgiou, G.; Inoue, Y.; Manconi, M.; Oertel, W.; Ondo, W.; Winkelmann, J.; Allen, R.P. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med., 2016, 21, 1-11.
[http://dx.doi.org/10.1016/j.sleep.2016.01.017] [PMID: 27448465]
[83]
Williams, A.M.; Garcia-Borreguero, D. Management of restless legs syndrome augmentation. Curr. Treat. Options Neurol., 2009, 11(5), 327-332.
[http://dx.doi.org/10.1007/s11940-009-0036-2] [PMID: 19744398]
[84]
Ferré, S.; García-Borreguero, D.; Allen, R.P.; Earley, C.J. New Insights into the neurobiology of restless legs syndrome. Neuroscientist, 2019, 25(2), 113-125.
[http://dx.doi.org/10.1177/1073858418791763] [PMID: 30047288]
[85]
Garcia-Borreguero, D.; Allen, R.; Hudson, J.; Dohin, E.; Grieger, F.; Moran, K.; Schollmayer, E.; Smit, R.; Winkelman, J. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study. Curr. Med. Res. Opin., 2016, 32(1), 77-85.
[http://dx.doi.org/10.1185/03007995.2015.1103216] [PMID: 26569149]
[86]
Maestri, M.; Fulda, S.; Ferini-Strambi, L.; Zucconi, M.; Marelli, S.; Staedler, C.; Bassetti, C.L.; Manconi, M. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med., 2014, 15(5), 570-575.
[http://dx.doi.org/10.1016/j.sleep.2014.01.016] [PMID: 24767724]
[87]
Garcia-Borreguero, D.; Cano-Pumarega, I.; Marulanda, R. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease). Sleep Med. Rev., 2018, 41, 50-60.
[http://dx.doi.org/10.1016/j.smrv.2018.01.001] [PMID: 29602660]
[88]
Giannaki, C.D.; Hadjigeorgiou, G.M.; Karatzaferi, C.; Maridaki, M.D.; Koutedakis, Y.; Founta, P.; Tsianas, N.; Stefanidis, I.; Sakkas, G.K. A single-blind randomized controlled trial to evaluate the effect of 6 months of progressive aerobic exercise training in patients with uraemic restless legs syndrome. Nephrol. Dial. Transplant., 2013, 28(11), 2834-2840.
[http://dx.doi.org/10.1093/ndt/gft288] [PMID: 23929523]
[89]
Aukerman, M.M.; Aukerman, D.; Bayard, M.; Tudiver, F.; Thorp, L.; Bailey, B. Exercise and restless legs syndrome: a randomized controlled trial. J. Am. Board Fam. Med., 2006, 19(5), 487-493.
[http://dx.doi.org/10.3122/jabfm.19.5.487] [PMID: 16951298]
[90]
Lettieri, C.J.; Eliasson, A.H. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest, 2009, 135(1), 74-80.
[http://dx.doi.org/10.1378/chest.08-1665] [PMID: 19017878]
[91]
Lin, Y.C.; Feng, Y.; Zhan, S.Q.; Li, N.; Ding, Y.; Hou, Y.; Wang, L.; Lin, H.; Sun, Y.; Huang, Z.Y.; Xue, Q.; Wang, Y.P. Repetitive transcranial magnetic stimulation for the treatment of restless legs syndrome. Chin. Med. J. (Engl.), 2015, 128(13), 1728-1731.
[http://dx.doi.org/10.4103/0366-6999.159344] [PMID: 26112711]
[92]
Pan, W.; Wang, M.; Li, M.; Wang, Q.; Kwak, S.; Jiang, W.; Yamamoto, Y. Actigraph evaluation of acupuncture for treating restless legs syndrome. Evid. Based Complement. Alternat. Med., 2015, 2015343201
[http://dx.doi.org/10.1155/2015/343201] [PMID: 25763089]
[93]
Mitchell, U.H.; Myrer, J.W.; Johnson, A.W.; Hilton, S.C. Restless legs syndrome and near-infrared light: An alternative treatment option. Physiother. Theory Pract., 2011, 27(5), 345-351.
[http://dx.doi.org/10.3109/09593985.2010.511440] [PMID: 20977377]
[94]
Mitchell, U.H.; Johnson, A.W.; Myrer, B. Comparison of two infrared devices in their effectiveness in reducing symptoms associated with RLS. Physiother. Theory Pract., 2011, 27(5), 352-359.
[http://dx.doi.org/10.3109/09593985.2010.502210] [PMID: 20950168]
[95]
Burbank, F.; Buchfuhrer, M.J.; Kopjar, B. Sleep improvement for restless legs syndrome patients. Part I: pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RLS symptoms. Res. Rev. Parkinsonism, 2013, 3, 1-10.
[96]
Happe, S.; Evers, S.; Thiedemann, C.; Bunten, S.; Siegert, R. Whole body and local cryotherapy in restless legs syndrome: A randomized, single-blind, controlled parallel group pilot study. J. Neurol. Sci., 2016, 370, 7-12.
[http://dx.doi.org/10.1016/j.jns.2016.09.006] [PMID: 27772790]
[97]
Innes, K.E.; Selfe, T.K. The effects of a gentle yoga program on sleep, mood, and blood pressure in older women with restless legs syndrome (RLS): A Preliminary Randomized Controlled Trial. Evid. Based Complement. Alternat. Med., 2012, 2012294058
[http://dx.doi.org/10.1155/2012/294058] [PMID: 22474497]
[98]
Harrison, E.G.; Keating, J.L.; Morgan, P.E. Non-pharmacological interventions for restless legs syndrome: a systematic review of randomised controlled trials. Disabil. Rehabil., 2019, 41(17), 2006-2014.
[http://dx.doi.org/10.1080/09638288.2018.1453875] [PMID: 29561180]
[99]
Chen, Q.; Wang, Q.; Ding, S.; Li, S.; Zhang, Y.; Chen, S.; Lin, X.; Li, C.; Asakawa, T. Problems lowering the study quality in traditional medicine, introspection from an example of meta-analysis of acupuncture. BMC Complement. Med. Ther., 2020, 20(1), 41.
[http://dx.doi.org/10.1186/s12906-019-2806-z] [PMID: 32046689]
[100]
Brewer, K.L.; Baran, C.A.; Whitfield, B.R.; Jensen, A.M.; Clemens, S. Dopamine D3 receptor dysfunction prevents anti-nociceptive effects of morphine in the spinal cord.Front. Neural Circuits, 2014, 8, 62.,
[http://dx.doi.org/10.3389/fncir.2014.00062] [PMID: 24966815]

Rights & Permissions Print Cite
Article Metrics
35
1
© 2024 Bentham Science Publishers | Privacy Policy